Sign In
Buy LFCR
$4.42
+0.0600 (+1.38%)
At Close: Jul 31, 2026
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
07:00am, Tuesday, 22'nd Apr 2025
CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect
10:00am, Thursday, 17'th Apr 2025
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Com
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 16'th Apr 2025
CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today a
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Com
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer
07:00am, Monday, 14'th Apr 2025
Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore's Capabilities Acros
NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Com
NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Com
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Comp
Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript
07:43pm, Thursday, 03'rd Apr 2025
Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q3 2025 Earnings Conference Call April 3, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, IR Paul Josephs - CEO Ryan Lake - CFO Conference Call
Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates
06:21pm, Thursday, 03'rd Apr 2025
Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.05 per share a year ago.
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update
04:05pm, Thursday, 03'rd Apr 2025
-- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 -- -- Signed Multiple Development Agreements with New and Existing Customers --
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company")
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company")
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company"
